Insulin-independent glucose uptake in skeletal muscle by coupled SGLT and Na,K-ATPase transport

Read full text Summarise with VIRAT
Authors: Natalie J. Norman, Tatiana L. Radzyukevich, Peter Chomczynski, Michal Rymaszewski, Izabela Fokt, Waldemar Priebe, Lucas Schmidt, Tiffany Zhu, Bryan Mackenzie, Julio Alberto Landero Figueroa, Judith A. Heiny
Cited by: 0
References: 49

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Exercise is a cornerstone therapy for diabetes because working skeletal muscles take up glucose at dramatically greater rates than postprandial insulin-stimulated glucose uptake and, notably, do so without a requirement for insulin. This remarkable ability of working muscles is preserved in diabetes, when muscles become resistant to insulin. However, the mechanism of insulin- in dependent glucose uptake by working muscles is not fully understood. Here we describe a previously unrecognized glucose uptake pathway in muscle, which we refer to as “mSGLT” based on shared properties with the Sodium Glucose Linked Transporter family. In contrast to the abundant GLUT4 transporter, mSGLT is not regulated by insulin, requires Na,K-ATPase-α2 activity, and transports the hexose α-methyl-D-glucoside (αMDG), a glucose derivative that is handled by SGLTs but not GLUT4. The mSGLT pathway and GLUT transport pathways are independent and additive. In addition to exercise, mSGLT imports glucose under other conditions of adrenergic stimulation, which inhibits pancreatic insulin release and reduces the insulin sensitivity of muscle. SGLT2-specific antibodies recognize a protein in muscle of similar size to the kidney SGLT2; this protein localizes to the muscle t-tubules, together with Na,K-ATPase-α2 and MAP17, the regulatory subunit of SGLT2. However, skeletal muscles do not express a full-length transcript of S lc5a2 (SGLT2), and SGLT2-specific inhibitors do not inhibit mSGLT with high affinity. The novel transporter may be a muscle variant of Slc5a2 that results from post-transcriptional or post-translational mechanisms. mSGLT and its regulation offer potential muscle-specific therapeutic targets for treating hyperglycemia and other conditions when insulin-stimulated glucose disposal into muscle is impaired.

Fields of Study & Subjects

Metabolism Diabetes and Cancer Ion Transport and Channel Regulation Diabetes Treatment and Management

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
27 March 2026
Language
EN
Document type
Preprint